Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

scientific article

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1476-5381.2012.01849.X
P932PMC publication ID3419910
P698PubMed publication ID22233293

P2093author name stringChao Cheng
Fang Wang
Xu Zhang
Li-wu Fu
Xiao-kun Wang
Yong-ju Liang
Hong-bing Huang
Wang Zhou
Wen-jing Zhou
Kenneth Kin Wah To
P2860cites workAkt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxolQ40036920
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistanceQ40050525
Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivoQ40345597
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.Q40410062
Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.Q40530013
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.Q40561425
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.Q40904151
Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugationQ43072077
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.Q43739398
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.Q44183117
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.Q44373949
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.Q44450066
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistanceQ44687014
Screening novel, potent multidrug-resistant modulators from imidazole derivativesQ45011364
Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitorsQ84966132
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceQ24645668
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodQ25938999
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerQ27851410
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaQ27851421
Cell signaling by receptor tyrosine kinasesQ27860474
Oncogenic kinase signallingQ28189493
The human ATP-binding cassette (ABC) transporter superfamilyQ28204495
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport functionQ28475378
Tumour stem cells and drug resistanceQ29617742
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)Q33194199
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriersQ33235069
Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathwayQ33296974
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasisQ33588267
Biochemical, cellular, and pharmacological aspects of the multidrug transporterQ33636699
The human ATP-binding cassette (ABC) transporter superfamily.Q34083168
Guide to Receptors and Channels (GRAC), 5th editionQ34228968
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsQ34625881
Smart drugs: tyrosine kinase inhibitors in cancer therapyQ34710595
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Q34743441
Activation of the PI3K/Akt pathway and chemotherapeutic resistanceQ35046899
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.Q35048738
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsQ35924859
Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.Q36125609
Targeting HER1/EGFR in cancer therapy: experience with erlotinibQ36429516
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.Q36536479
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapyQ36593180
Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).Q36691571
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinibQ37000538
Genomics and the mechanism of P-glycoprotein (ABCB1).Q37023913
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2Q37119716
Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Q37853578
ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistanceQ38510908
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancerQ39574492
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport functionQ39877772
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.Q39881351
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectmultiple drug resistanceQ643839
crizotinibQ5186964
P304page(s)1669-1683
P577publication date2012-07-01
P1433published inBritish Journal of PharmacologyQ919631
P1476titleCrizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
P478volume166

Reverse relations

cites work (P2860)
Q64054594A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma
Q28541630A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells
Q35171274ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors
Q37739472Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
Q45404446Apoptosis sensitization by Euphorbia factor L1 in ABCB1-mediated multidrug resistant K562/ADR cells.
Q89145785Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Q39016059Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy.
Q58097458Comparative Gene Expression Analysis in WM164 Melanoma Cells Revealed That --Dimethylacrylshikonin Leads to ROS Generation, Loss of Mitochondrial Membrane Potential, and Autophagy Induction
Q39416426Crizotinib for the treatment of non-small-cell lung cancer
Q42373819Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
Q49843204Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
Q36212765Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway
Q37707577Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro
Q28069761Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?
Q38859977Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon.
Q36689070Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
Q47100454Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates
Q38847914Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer
Q35633633Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.
Q35860275Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice
Q46041746Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Q28553930Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines
Q51069180Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
Q37697125Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis
Q96304650Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro
Q39202090Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein
Q38718947Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
Q35978108Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer
Q38242601Pharmacogenetics of membrane transporters: a review of current approaches.
Q39031326Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.
Q38366828Pharmacokinetics of crizotinib in NSCLC patients.
Q38984689Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma
Q33751197Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
Q90347564Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
Q90274971Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
Q96304537Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
Q51572037Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro.
Q58097468Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells
Q36887730The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines
Q35016736Transgenic plants as low-cost platform for chemotherapeutic drugs screening
Q36709217Tubulin-targeting agent combination therapies: dosing schedule could matter
Q49888021Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.